CRP and non-small cell lung carcinoma: Measuring CRP over the course of treatment and in our case for NSCLC patients at treatment cycle 3 and cycle 2 allows monitoring of the inflammatory level and offers the potential to become a promising prognostic marker to better guide treatment decisions.